GelStat Corporation's CEO Issues Letter to Shareholders Discussing Recent Events
October 23 2012 - 9:27AM
Marketwired
GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare
company primarily focused on the development and marketing of
over-the-counter (OTC) products for the safe and effective
treatment of pain, inflammation and sleep disorders, issues a
letter by its CEO to shareholders discussing recent events.
To Valued Shareholders and the Investment Community,
I am pleased to announce that the Company has recently filed its
form 10Ks for 2005, 2006, 2007 and 2008 as well as its form 10Qs
for the first, second and third quarters of 2006, 2007 and 2008
with the Securities and Exchange Commission. These filings fill the
gap from when the Company made its last filing for the third
quarter of 2005 and when the Company filed its form 15 in January
of 2009 to suspend reporting requirements. GelStat is now
positioned to file a form 10 and become a fully reporting company
or file the required documents to become an alternative reporting
company on the OTC Markets. Either decision will provide better
transparency to the investment community.
Moving forward here are the primary objectives:
- Select and sign a marketing partner to launch a significant
direct-to-consumer marketing campaign to promote GelStat Migraine
and GelStat Sleep;
- Create a Scientific Advisory Board;
- Report the Company's audited results for 2009, 2010 and
2011;
- Identify acquisitions to accelerate revenues and cash
flows;
- Secure the rights to additional healthcare related products;
and
- Strengthen the Company's financial condition.
We have already made significant progress on a number of the
aforementioned objectives and expect to be releasing additional
information soon.
Sincerely,
Gerald N. Kieft Chief Executive Officer GelStat Corporation
Make sure you are first to receive timely information on GelStat
Corporation when it hits the newswire. Sign up for GelStat's email
news alert system today at:
http://ir.stockpr.com/gelstat/request-information
ABOUT GELSTAT CORPORATION
GelStat Corporation is dedicated to providing safe and effective
over-the-counter (OTC) treatments for pain, inflammation and sleep
disorders. GelStat's first two products GelStat Migraine and
GelStat Sleep are sold through direct-to-consumer channels as well
as in a limited number of independent retailers and pharmacies. The
Company also has a suite of additional healthcare products in
various stages of development that address large consumer markets.
For more information, visit www.gelstat.com.
Safe Harbor Statement
This press release and the shareholder letter contains
forward-looking statements including pursuing strategic
relationships, building and leveraging a direct-to consumer
platform to launch new products, acquiring or licensing the rights
to products with proven science, growing organically and achieving
each of the goals mentioned above. Forward-looking statements can
be identified by words such as "anticipates," "intends," "plans,"
"seeks," "believes," "estimates," "expects" and similar references
to future periods.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. We caution you therefore against
relying on any of these forward-looking statements. They are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include the failure of our products to be accepted,
failure to obtain partners to market and distribute our products,
unanticipated delays in launching website or failure of the website
to generate revenues, our inability to find a target to acquire on
mutually acceptable terms, and the inability to get our reports
prepared and filed timely as a result of unforeseen audit
issues.
Any forward-looking statement made by us in this press release
speaks only as of the date on which it is made. Factors or events
that could cause our actual results to differ may emerge from time
to time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
FOR ADDITIONAL INFORMATION CONTACT: Gerald Kieft CEO GelStat
Corporation 772-283-0020
GelStat (PK) (USOTC:GSAC)
Historical Stock Chart
From Nov 2024 to Dec 2024
GelStat (PK) (USOTC:GSAC)
Historical Stock Chart
From Dec 2023 to Dec 2024